Corvus Pharmaceuticals (CRVS) Competitors $8.19 -0.33 (-3.87%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRVS vs. IMNM, ENLV, AYTU, COGT, LBPH, AMPH, AKRO, NAMS, RXRX, and SRRKShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Immunome (IMNM), Enlivex Therapeutics (ENLV), Aytu BioPharma (AYTU), Cogent Biosciences (COGT), Longboard Pharmaceuticals (LBPH), Amphastar Pharmaceuticals (AMPH), Akero Therapeutics (AKRO), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Immunome Enlivex Therapeutics Aytu BioPharma Cogent Biosciences Longboard Pharmaceuticals Amphastar Pharmaceuticals Akero Therapeutics NewAmsterdam Pharma Recursion Pharmaceuticals Scholar Rock Corvus Pharmaceuticals (NASDAQ:CRVS) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking. Does the media favor CRVS or IMNM? In the previous week, Corvus Pharmaceuticals had 9 more articles in the media than Immunome. MarketBeat recorded 18 mentions for Corvus Pharmaceuticals and 9 mentions for Immunome. Corvus Pharmaceuticals' average media sentiment score of 0.64 beat Immunome's score of -0.09 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, CRVS or IMNM? Corvus Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Do insiders and institutionals have more ownership in CRVS or IMNM? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer CRVS or IMNM? Corvus Pharmaceuticals presently has a consensus target price of $12.83, indicating a potential upside of 56.70%. Immunome has a consensus target price of $28.83, indicating a potential upside of 191.10%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, CRVS or IMNM? Corvus Pharmaceuticals has higher earnings, but lower revenue than Immunome. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.93-8.81Immunome$10.78M55.16-$106.81M-$8.11-1.22 Does the MarketBeat Community favor CRVS or IMNM? Corvus Pharmaceuticals received 258 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 61.75% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes28961.75% Underperform Votes17938.25% ImmunomeOutperform Votes3173.81% Underperform Votes1126.19% Is CRVS or IMNM more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Immunome's return on equity of -48.36% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Immunome -3,014.59%-48.36%-41.71% SummaryCorvus Pharmaceuticals beats Immunome on 10 of the 18 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$512.28M$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-8.8110.92101.9217.46Price / SalesN/A245.131,196.9569.07Price / CashN/A53.4941.0436.36Price / Book40.959.306.345.87Net Income-$27.03M$154.14M$119.64M$225.66M7 Day Performance-13.33%-9.47%-5.13%-1.34%1 Month Performance13.59%-7.30%-2.72%1.15%1 Year Performance464.83%28.21%31.10%24.02% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.5198 of 5 stars$8.19-3.9%$12.83+56.7%+493.5%$512.28MN/A-8.8130Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeIMNMImmunome1.4338 of 5 stars$12.37-1.0%N/A+24.9%$742.82M$14.02M-1.6140Analyst ForecastAnalyst RevisionNews CoverageENLVEnlivex Therapeutics3.1073 of 5 stars$1.19-0.8%N/A-38.5%$25.37MN/A-1.0070Short Interest ↑News CoverageAYTUAytu BioPharma1.348 of 5 stars$1.86+7.1%N/A-30.5%$11.44M$81M-0.65160Short Interest ↓News CoverageGap UpCOGTCogent Biosciences2.7273 of 5 stars$10.88+4.8%N/A+20.6%$1.19BN/A-4.3980Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLBPHLongboard Pharmaceuticals1.5222 of 5 stars$59.79+0.1%N/A+1,180.9%$2.33BN/A-26.8120Short Interest ↓AMPHAmphastar Pharmaceuticals4.8623 of 5 stars$46.60-2.3%N/A-20.6%$2.24B$644.40M15.531,761Insider SellingAKROAkero Therapeutics4.0236 of 5 stars$32.08-0.9%N/A+94.5%$2.24BN/A-8.5530Earnings ReportShort Interest ↓Analyst RevisionNews CoverageNAMSNewAmsterdam Pharma3.0131 of 5 stars$24.47-1.2%N/A+150.5%$2.20B$14.09M0.0057Short Interest ↑News CoverageRXRXRecursion Pharmaceuticals2.1201 of 5 stars$7.81+3.0%N/A-7.4%$2.20B$44.58M-5.10400Insider SellingSRRKScholar Rock4.6067 of 5 stars$27.09+1.6%N/A+125.3%$2.13B$33.19M-11.53140Analyst ForecastAnalyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies Immunome Alternatives Enlivex Therapeutics Alternatives Aytu BioPharma Alternatives Cogent Biosciences Alternatives Longboard Pharmaceuticals Alternatives Amphastar Pharmaceuticals Alternatives Akero Therapeutics Alternatives NewAmsterdam Pharma Alternatives Recursion Pharmaceuticals Alternatives Scholar Rock Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRVS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
